With advances in in vitro transcription techniques from plasmid-based DNA templates or from plasmid-amplified DNA PCR, as well as advances in delivery vehicles including polymer- and lipid-based nanoparticles, the use of RNA molecules has increased. of increasing interest, including mRNA molecules as therapeutics for human disease. Examples include loss-of-function mutations such as adenosine deaminase deficiency, ornithine transcarbamylase deficiency, phenylketonuria, hemophilia B, and cystic fibrosis. There has also been interest in the use of mRNA as an alternative to attenuated viruses, inactivated viruses, or protein subunits during vaccine development.
Examples of alternative therapies for inactivating mutations causing diseases or different mRNA candidates as vaccine candidates have entered various stages of preclinical or clinical development as therapeutics for their target diseases. In fact, as of April 2020, one of the five COVID-19 vaccine candidates confirmed to be in clinical development employs an mRNA-based platform to inoculate against the novel coronavirus. Compared to more traditional platforms, mRNAs are attractive candidates for various therapeutic applications due to their low toxicity, low immunogenicity, production cost, and other factors. Therefore, the use of mRNA as a therapeutic modality may increase substantially in the future. Improvements in the cost and ease of synthesizing mRNA from DNA templates or by chemical synthesis methods, mRNA stability, translation efficiency, or reduced immunogenicity may facilitate the therapeutic use of mRNA.
Creative Biogene's mRNA-related kits help you overcome these challenges in your mRNA workflow. Of these, our extraction kits enable mRNA recovery rates consistently above 90%, minimize poly(A) RNA loss and eliminate the risk of RNase degradation. Please browse our RNA kits to find what you're looking for.